540 related articles for article (PubMed ID: 17910520)
1. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Arca M; Gaspardone A
Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
[TBL] [Abstract][Full Text] [Related]
4. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
[TBL] [Abstract][Full Text] [Related]
5. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
8. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
[TBL] [Abstract][Full Text] [Related]
9. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
[TBL] [Abstract][Full Text] [Related]
10. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J; Waters DD;
Lancet; 2006 Sep; 368(9539):919-28. PubMed ID: 16962881
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
13. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
14. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
[TBL] [Abstract][Full Text] [Related]
15. [Atorvastatin in secondary prevention].
Ongen Z; Yilmaz Y; Karadağ B
Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():23-8. PubMed ID: 19404047
[TBL] [Abstract][Full Text] [Related]
16. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
17. Expanding roles for atorvastatin.
Singh V; Deedwania P
Drugs Today (Barc); 2008 Jun; 44(6):455-71. PubMed ID: 18596999
[TBL] [Abstract][Full Text] [Related]
18. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
[TBL] [Abstract][Full Text] [Related]
19. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
[TBL] [Abstract][Full Text] [Related]
20. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]